← Patent-cliff monitor small molecule SCEMBLIX ASCIMINIB HYDROCHLORIDE
Loss of exclusivity May 2040 latest FDA-listed patent expiry
Company Novartis → See this company's full patent-cliff portfolio Drug detail Brand name SCEMBLIX Active ingredient ASCIMINIB HYDROCHLORIDE Strength EQ 100MG BASE Dosage form TABLET Route ORAL Modality Small molecule FDA approval April 2024 Marketing status RX
Listed patents Patent Expires Type 12252479 May 2040 use U-1374 12252478 May 2040 product 11407735 May 2040 substance 8829195 October 2035 substance
Regulatory exclusivity Code Expires ODE* October 2028 M-318 October 2028 NCE October 2026
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.